warfarin in English

noun
1
a water-soluble compound with anticoagulant properties, used as a rat poison and in the treatment of thrombosis.
Omitted prescription medications included such drugs as oxycodone, warfarin , and insulin.
noun
    coumadin

Use "warfarin" in a sentence

Below are sample sentences containing the word "warfarin" from the English Dictionary. We can refer to these sentence patterns for sentences in case of finding sample sentences with the word "warfarin", or refer to the context using the word "warfarin" in the English Dictionary.

1. Common anticoagulants include warfarin and heparin.

2. Warfarin sodium (Coumadin) is an Anticoagulant medicine

3. Warfarin sodium is an Anticoagulant medication

4. Warfarin is also used in antiphospholipid syndrome.

5. Learn and reinforce your understanding of Anticoagulants: Warfarin through video

6. Coumadin is a brand name for the drug warfarin.

7. Warfarin, a powerful blood thinner often sold under the brand names Coumadin, Taro-Warfarin and Apo-Warfarin can cause serious bleeding, especially if taken together with acetylsalicylic acid (ASA) or certain other drugs, and thus should be used under a doctor's care with regular blood testing.

8. Navigating the different direct oral Anticoagulants and warfarin can be confusing

9. What drugs alter prothrombin time by interacting with warfarin levels ( pharmacokinetics )?

10. Achieved, the parenteral Anticoagulant should be discontinued and the warfarin continued

11. Warfarin administration in the second and third trimesters is much less commonly associated with birth defects, and when they do occur, are considerably different from fetal warfarin syndrome.

12. Warfarin has a long half-life and need only be given once a day.

13. Many drug interactions can increase the effect of warfarin, also causing an overdose.

14. Allopurinol may increase the effect of warfarin and other drugs that thin the blood

15. But the Anticoagulant effect of warfarin must be carefully monitored with periodic blood tests

16. Despite the promise of pharmacogenomic testing in warfarin dosing, its use in clinical practice is controversial.

17. Anticoagulants such as heparin or warfarin (also called Coumadin) slow down your body's process of making clots

18. Objective To investigate the safety and efficiency of ticlopidine and warfarin on intracardiac mural thrombus.

19. Cloves can increase the risk of bleeding by enhancing the effects of blood-thinning medications, like Warfarin

20. Warfarin is used to cull vampire bat populations in areas where human–wildlife conflict is a concern.

21. The maintenance dose of warfarin can fluctuate significantly depending on the amount of vitamin K1 in the diet.

22. The U.S. Food and Drug Administration (FDA) product insert on warfarin states that alcohol should be avoided.

23. To provide a strategy for the management of warfarin therapy in Ambulatory adult patients using a standardized process while offering an individualized assessment

24. Conclusion Warfarin for the treatment of elderly persistent atrial fibrillation is both efficient and safe when INR can be maintained between 8-

25. The initial PROTECT-AF trial showed superiority (i.e. composite endpoint of stroke, embolism and cardiovascular death) of the WATCHMANTM compared to warfarin.

26. Apart from the metabolic interactions, highly protein bound drugs can displace warfarin from serum albumin and cause an increase in the INR.

27. The most common congenital abnormalities associated with warfarin use in late pregnancy are central nervous system disorders, including spasticity and seizures, and eye defects.

28. The WATCHMAN® device proved to be non-inferior to oral anticoagulation with warfarin in the PROTECT-AF trial in terms of safety and efficacy.

29. Warfarin continues to be the most widely used oral Anticoagulant but the use of the newer oral Anticoagulants (dabigatran etexilate, rivaroxaban and apixaban) is increasing

30. Anticoagulant medications, which include warfarin, heparin, low-molecular weight heparin, and direct oral Anticoagulants, are one of four medication classes commonly identified as a cause of ADEs

31. The British Heart Foundation published that those on Anticoagulants (mainly warfarin) should be cautious to make sure that they don't bleed too much at the injection site

32. There are three main types of blood thinners that patients commonly take: Anticoagulants like warfarin or heparin, antiplatelet drugs like aspirin, and fibrinolytics like tPA (tissue plasminogen activator).

33. The idea of Bridging to warfarin using heparin or a low molecular weight heparin (LMWH, such as enoxaparin) is deeply engrained in pharmacy students and medical residents early in their education

34. Predicting risk with oral Anticoagulants Apixaban (Eliquis), dabigatran (Pradaxa), rivaroxaban (Xarelto) and warfarin (Coumadin or Marevan) can all be considered for the prevention of stroke and systemic embolism in adults with non-valvular atrial fibrillation.

35. Warfarin is best suited for anticoagulation (clot formation inhibition) in areas of slowly running blood (such as in veins and the pooled blood behind artificial and natural valves) and in blood pooled in dysfunctional cardiac atria.

36. Anticoagulants such as heparin or warfarin (also called Coumadin) slow down your body's process of making clots. Antiplatelet drugs, such as aspirin, prevent blood cells called platelets from clumping together to form a clot

37. ‘Bridging” is a term that refers to the use of short-acting anticoagulants (heparin or LMWH) for a period of time during interruption of warfarin therapy when the INR is not within a therapeutic range

38. Bridging anticoagulation refers to giving a short-acting blood thinner, usually low-molecular-weight heparin given by subcutaneous injection for 10 to 12 days around the time of the surgery/procedure, when warfarin is interrupted and its anticoagulant effect is outside a therapeutic range

39. Drugs such as ketotifen, doxepin, H2-blockers, glucocorticoids, leukotriene receptor antagonists, COX-2-inhibitors, antimalarials, dapsone, sulfasalazine, antibiotics, acyclovir, nifedipine, danazol, terbutaline, warfarin, histaglobin, cyclosporine, tacrolimus, methotrexate, cyclophosphamide and intravenous immunoglobulin are reviewed as well as measures such as plasmapheresis, phototherapy, diet and psychosomatic treatment.

40. ‘The Cryptogenic subgroup appeared to fare better with warfarin, but investigators believe some of these patients have a tendency to form blood clots in the heart.’ ‘When constrictive bronchiolitis occurs with no identifiable cause, it is referred to as Cryptogenic constrictive bronchiolitis.’

41. ‘The Cryptogenic subgroup appeared to fare better with warfarin, but investigators believe some of these patients have a tendency to form blood clots in the heart.’ ‘When constrictive bronchiolitis occurs with no identifiable cause, it is referred to as Cryptogenic constrictive bronchiolitis.’

42. Section 4.4.1 - Percutaneous Approaches to Occlude the Left Atrial Appendage Section 6.3.4 - Catheter Ablation in HF Section 7.4 - Complicating Acute Coronary Syndrome Section 7.12 - Device Detection of AF and Atrial Flutter Section 7.13 - Weight Loss NOACs are recommended over warfarin where eligible except in those patients with moderate - severe

43. The Aristophanes study is a large retrospective observational study with real-world data pooled from 5 data sources in the United States, in order to compare stroke/systemic embolism (SE) and major bleeding (MB) among nonvalvular atrial fibrillation patients treated with either non-vitamin K antagonist oral anticoagulants (NOACs) or warfarin.

44. Although specific interaction studies were not conducted for all medicinal products, population pharmacokinetic analysis showed no effect of concomitant medication on sildenafil pharmacokinetics when grouped as CYP#C# inhibitors (such as tolbutamide, warfarin, phenytoin), CYP#D# inhibitors (such as selective serotonin reuptake inhibitors, tricyclic antidepressants), thiazide and related diuretics, loop and potassium sparing diuretics, angiotensin converting enzyme inhibitors, calcium channel blockers, beta-adrenoreceptor antagonists or inducers of CYP# metabolism (such as rifampicin, barbiturates